Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER vs DOCA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Isolyte E in Dextrose 5% provides fluid, electrolytes, and calories. Dextrose is metabolized to carbon dioxide and water, yielding energy. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain acid-base balance and osmotic pressure.
Desoxycorticosterone acetate (DOCA) is a mineralocorticoid hormone that binds to mineralocorticoid receptors in the distal renal tubules, promoting sodium reabsorption and potassium excretion, leading to increased extracellular fluid volume and blood pressure.
FDA-approved: For intravenous administration as a source of water, electrolytes, and calories in patients requiring fluid and electrolyte replacement.,Off-label: Not typically used off-label; primarily for maintenance or replacement therapy.
Adrenocortical insufficiency (Addison's disease),Salt-losing adrenogenital syndrome
Intravenous infusion; typical adult dose is 1000-2000 m L per day (30 m L/kg/day) adjusted for fluid and electrolyte needs; rate based on clinical status.
Desoxycorticosterone acetate (DOCA) is administered intramuscularly at a dose of 2 to 5 mg daily or 10 mg every 12 hours initially, then reduced to 1 to 2 mg daily or every other day for maintenance. Alternatively, a pellet implant of 125 mg or 250 mg can be used for prolonged effect.
Not applicable; components are endogenous substances. Dextrose half-life ~15-20 min after infusion; electrolytes distribute and are cleared renally with half-lives dependent on renal function.
30-35 minutes; clinical context: short duration necessitates frequent dosing or continuous infusion for sustained effect.
Dextrose undergoes glycolysis and the citric acid cycle; electrolytes are not metabolized but are excreted or incorporated into body pools.
Primarily hepatic metabolism via reduction and conjugation; little is known about specific CYP enzymes.
ISOLYTE E in Dextrose 5% is a balanced electrolyte solution with glucose. Electrolytes are primarily excreted renally; water and dextrose are metabolized. Biliary/fecal excretion is negligible. Dextrose is metabolized to CO2 and water.
Primarily renal as metabolites; <5% unchanged. Biliary/fecal elimination is negligible (<2%).
None for electrolytes and dextrose; sodium, potassium, chloride, magnesium, acetate, and gluconate are free ions in solution.
~70% bound to plasma proteins (primarily albumin).
Sodium and chloride distribute primarily in extracellular fluid (~0.2 L/kg). Dextrose distributes in total body water (~0.6 L/kg). Potassium distributes in intracellular fluid (~0.6 L/kg after equilibration).
Vd: 0.8-1.2 L/kg; indicates extensive tissue distribution with rapid redistribution from effect sites.
100% intravenous; not administered by other routes.
Oral: <5% due to extensive first-pass metabolism; IM/SC: 100%.
In renal impairment (e GFR < 30 m L/min/1.73m²), reduce total volume to 500-1000 m L/day with careful monitoring of potassium, sodium, and glucose; avoid if hyperkalemia or fluid overload.
No specific dose adjustment is recommended for impaired renal function, but monitor for fluid retention and hypertension. Use with caution in patients with significant renal impairment.
No specific dose adjustment for Child-Pugh class; monitor for fluid overload and electrolyte imbalances; in severe hepatic impairment, reduce volume to 500-1000 m L/day.
No specific dose adjustment for hepatic impairment, but use with caution due to potential electrolyte disturbances.
Weight-based: 20-50 m L/kg/day for maintenance; neonates and infants: 100-150 m L/kg/day; adjust based on glucose, electrolytes, and hydration status; maximum rate 4 m L/kg/hour for neonates.
Dose is not well established; use 0.1 to 0.2 mg/kg intramuscularly daily or adjust based on clinical response and serum electrolytes.
Start with lower volumes (500-1000 m L/day) due to decreased renal function and risk of fluid overload; monitor serum electrolytes, glucose, and central venous pressure.
Start at the lower end of the dosing range (e.g., 1 to 2 mg IM daily) and monitor closely for fluid overload, hypertension, and electrolyte imbalances due to age-related decreased renal function and comorbidities.
Not applicable; no FDA boxed warning exists for this product.
None
Monitor serum electrolytes, fluid balance, and glucose levels; avoid fluid overload in patients with cardiac or renal impairment; risk of hyperglycemia in diabetic patients; use with caution in patients with metabolic alkalosis or hypokalemia.
Fluid overload and edema,Hypokalemia,Hypertension,Cardiac hypertrophy and failure,Increased risk of infection due to immune suppression when used with glucocorticoids
Hypersensitivity to any component; clinically significant hyperglycemia; severe metabolic acidosis; hyperkalemia (for potassium-containing formulations); hypermagnesemia; fluid overload conditions.
Hypersensitivity to desoxycorticosterone or any component,Severe renal impairment,Hyperkalemia,Hypocalcemia,Congestive heart failure,Systemic fungal infections
No specific food interactions known. Monitor electrolyte intake in patients with electrolyte imbalances.
No specific food interactions are reported. However, maintain consistent sodium intake; do not restrict salt unless advised. Avoid potassium-rich foods if potassium levels are high. Alcohol may increase the risk of electrolyte disturbances.
ISOLYTE E in Dextrose 5% is an intravenous electrolyte and carbohydrate solution. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Dextrose and electrolytes are considered essential nutrients and are generally safe when used as indicated. However, administration during labor and delivery may cause fluid and electrolyte imbalances. First trimester risks are theoretical; second and third trimesters may involve risks of maternal hyperglycemia and fetal hyperinsulinemia if dextrose infusion is excessive. No specific teratogenicity reported.
FDA Pregnancy Category C. First trimester: feminization of male fetuses, including hypospadias and clitoral hypertrophy, due to androgenic activity. Second and third trimesters: risk of virilization of female fetuses; no adequate human studies; avoid use unless potential benefit outweighs risk.
Dextrose and electrolytes are normal constituents of human milk. Following intravenous administration, concentrations in milk are expected to parallel maternal plasma levels. No specific M/P ratio is available. Use during breastfeeding is considered compatible; however, monitor for adverse effects in the infant such as electrolyte imbalance or hyperglycemia if maternal infusion is prolonged or high volume.
Excreted in breast milk in low amounts; M/P ratio not established. Potential for adverse effects in nursing infants (e.g., electrolyte disturbances, hypertension). Use caution; consider alternative therapies.
Pregnancy induces increased plasma volume and glomerular filtration rate, potentially diluting electrolytes and altering glucose metabolism. Dose adjustments may be required: consider lower dextrose infusion rates to avoid maternal hyperglycemia and fetal hyperinsulinemia. Monitor electrolytes closely; adjust potassium and magnesium supplementation as needed. No specific dose adjustment is universally recommended; individualize based on maternal weight, clinical status, and monitoring results.
No specific dose adjustments studied; monitor for increased volume of distribution and clearance; adjust based on clinical response and serum electrolyte levels. Use lowest effective dose.
ISOLYTE E in DEXTROSE 5% is an isotonic crystalloid solution for IV administration. Contains electrolytes (Na, K, Mg, Cl, acetate, gluconate) and dextrose 5%. Use with caution in patients with renal impairment, heart failure, or hyperkalemia. Monitor serum electrolytes, blood glucose, and fluid balance. Not for use as a sole source of nutrition. Do not administer if solution is discolored or contains particulates.
DOCA (desoxycorticosterone acetate) is a mineralocorticoid used in adrenal insufficiency. Monitor serum potassium closely due to risk of hypokalemia from excessive mineralocorticoid activity. DOCA requires intramuscular injection; do not administer intravenously. Use in conjunction with glucocorticoids to mimic cortisol's permissive effects on catecholamines. Avoid in patients with hypertension, heart failure, or renal impairment due to sodium and water retention.
Inform your healthcare provider about all medical conditions, especially kidney disease, heart failure, or diabetes.,Report any signs of allergic reaction such as rash, itching, or trouble breathing.,Tell your doctor if you experience swelling, shortness of breath, or irregular heartbeat.,This solution contains dextrose (sugar); monitor blood glucose if you have diabetes.,Do not use if the bag is damaged or solution is cloudy.
This medication helps maintain salt and water balance in the body.,It is given as an injection into a muscle; do not inject into a vein.,Report signs of excessive fluid retention: swelling in legs, rapid weight gain, shortness of breath.,Monitor for muscle cramps or weakness which may indicate low potassium levels.,Avoid salt substitutes containing potassium without consulting your doctor.,Do not miss appointments for injections as consistent dosing is critical.,Carry medical identification indicating you take corticosteroid replacement therapy.
No interactions on record
"Lidocaine, a sodium channel blocker and Class IB antiarrhythmic, inhibits hepatic CYP3A4, the primary enzyme responsible for the metabolism of quazepam, a benzodiazepine sedative-hypnotic. This inhibition reduces quazepam clearance, leading to elevated serum concentrations and enhanced sedative effects. Clinically, this may result in excessive sedation, respiratory depression, psychomotor impairment, and increased risk of falls, especially in elderly patients or those with hepatic impairment."
"Lidocaine and prilocaine are both amide-type local anesthetics that block voltage-gated sodium channels in neuronal membranes, inhibiting nerve impulse propagation. When used together, their systemic absorption can lead to additive cardiovascular and central nervous system toxicity, including arrhythmias, seizures, and methemoglobinemia, particularly with high doses or in patients with predisposing conditions."
"Lidocaine, a class Ib antiarrhythmic, inhibits CYP3A4, the primary enzyme responsible for the metabolism of ticagrelor, a P2Y12 platelet inhibitor. This inhibition can lead to increased plasma concentrations of ticagrelor, potentiating its antiplatelet effect and elevating the risk of major bleeding, such as gastrointestinal or intracranial hemorrhage. Conversely, reduced ticagrelor metabolism may also affect conversion to its active metabolite, though net effect still increases overall antiplatelet activity."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER vs DOCA, answered by our medical review team.
ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte E in Dextrose 5% provides fluid, electrolytes, and calories. Dextrose is metabolized to carbon dioxide and water, yielding energy. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain acid-base balance and osmotic pressure.. DOCA is a Mineralocorticoid that works by Desoxycorticosterone acetate (DOCA) is a mineralocorticoid hormone that binds to mineralocorticoid receptors in the distal renal tubules, promoting sodium reabsorption and potassium excretion, leading to increased extracellular fluid volume and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER and DOCA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; typical adult dose is 1000-2000 m L per day (30 m L/kg/day) adjusted for fluid and electrolyte needs; rate based on clinical status.. The standard adult dose of DOCA is: Desoxycorticosterone acetate (DOCA) is administered intramuscularly at a dose of 2 to 5 mg daily or 10 mg every 12 hours initially, then reduced to 1 to 2 mg daily or every other day for maintenance. Alternatively, a pellet implant of 125 mg or 250 mg can be used for prolonged effect.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER and DOCA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. ISOLYTE E in Dextrose 5% is an intravenous electrolyte and carbohydrate solution. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies h. DOCA is classified as Category C. FDA Pregnancy Category C. First trimester: feminization of male fetuses, including hypospadias and clitoral hypertrophy, due to androgenic activity. Second and third trimesters: ri. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.